First Line of Defense

Re-Balancing the Skin Microbiome and Innate Immune System to Improve Skin Health

The Antibiotic Era is ending

MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on developing and commercializing rational microbiome therapies for the top five dermatology and skin care conditions.

Recent scientific advances have demonstrated that some commensal bacteria, “Good Bugs” residing on human skin are beneficial to our immune defense. In contrast, colonization by “Bad Bugs”, for example Staph. aureus on the skin of patients with atopic dermatitis, is detrimental.

good-bugs-bad-bugs

Learn more about our Technology

Re-Balancing the Skin Microbiome & Innate Immune System

MatriSys Bioscience is a Clinical Stage Specialty Biopharmaceutical Company for the post antibiotic era.  Our company focuses on dermatology and skin care and develops therapeutics at the interface of the microbiome revolution and the innate immune system.  Historically bacteria have been considered as natural enemies that must be fought. However, recent advances in skin microbiome research have led to a better understanding of the mutualistic beneficial relationships that exist between the highly diverse skin microbial community and skin health.

Learn More

Commercialization

Our Intellectual Property offers multiple routes for commercialization: Rx Dermatology, Skin Care, and Cosmetic. Licensing discussions are currently underway for our first asset, S. hominis.